Literature DB >> 26960552

Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.

Xing-Li Meng1, Taniqua S Day1, Nathan McNeill1, Paula Ashcraft1, Thomas Frischmuth2, Seng H Cheng3, Zhi-Ping Liu4, Jin-Song Shen5, Raphael Schiffmann1.   

Abstract

Fabry disease is caused by deficient activity of α-galactosidase A and subsequent intracellular accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3). Vascular endothelial cells may play important roles in disease pathogenesis, and are one of the main target cell types in therapeutic interventions. In this study, we generated immortalized aortic endothelial cell lines from a mouse model of Fabry disease. These cells retained endothelial cell-specific markers and functions. Gb3 expression level in one of these clones (referred to as FMEC2) was highly susceptible to culture media, and appeared to be regulated by glucosylceramide synthase. Results also showed that Gb3 could be upregulated by hydrocortisone. FMEC2 express the mannose 6-phosphate receptor and sortilin but not the mannose receptor. Uptake studies suggested that sortilin plays a role in the binding and internalization of mammalian cell-produced α-galactosidase A. Moss-aGal (a plant-made enzyme) was endocytosed by FMEC2 via a receptor other than the aforementioned receptors. In conclusion, this study suggests that glucosylceramide synthase and hydrocortisone may play important roles in modulating Gb3 levels in Fabry mouse aortic endothelial cells, and that endocytosis of recombinant α-galactosidase A involves a combination of multiple receptors depending on the properties of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26960552     DOI: 10.1007/s10545-016-9920-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  36 in total

1.  Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.

Authors:  D F Moore; L T Scott; M T Gladwin; G Altarescu; C Kaneski; K Suzuki; M Pease-Fye; R Ferri; R O Brady; P Herscovitch; R Schiffmann
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

2.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

3.  Distribution of murine mannose receptor expression from early embryogenesis through to adulthood.

Authors:  K Takahashi; M J Donovan; R A Rogers; R A Ezekowitz
Journal:  Cell Tissue Res       Date:  1998-05       Impact factor: 5.249

4.  Beta4-galactosyltransferase-5 is a lactosylceramide synthase essential for mouse extra-embryonic development.

Authors:  Toshikazu Nishie; Yoko Hikimochi; Kota Zama; Yoshiyasu Fukusumi; Mitutoshi Ito; Haruka Yokoyama; Chie Naruse; Makoto Ito; Masahide Asano
Journal:  Glycobiology       Date:  2010-06-23       Impact factor: 4.313

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

6.  Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase.

Authors:  M S Nielsen; C Jacobsen; G Olivecrona; J Gliemann; C M Petersen
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

Review 7.  Fabry disease.

Authors:  Raphael Schiffmann
Journal:  Pharmacol Ther       Date:  2009-02-08       Impact factor: 12.310

8.  Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

Authors:  T Heare; N J Alp; D A Priestman; A B Kulkarni; P Qasba; T D Butters; R A Dwek; K Clarke; K M Channon; F M Platt
Journal:  J Inherit Metab Dis       Date:  2006-12-25       Impact factor: 4.982

9.  Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.

Authors:  Mario A Cabrera-Salazar; Matthew Deriso; Scott D Bercury; Lingyun Li; John T Lydon; William Weber; Nilesh Pande; Mandy A Cromwell; Diane Copeland; John Leonard; Seng H Cheng; Ronald K Scheule
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.

Authors:  D D Wagner; J B Olmsted; V J Marder
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.